The Food and Drug Administration yesterday published draft guidance to promote clinical studies to increase drug safety information for pregnant and nursing women and their providers. One document provides recommendations to facilitate studies to inform drug labeling for breastfeeding women. The other document includes recommendations on how to design studies to assess pregnancy outcomes in women taking FDA-regulated drugs and biological products during pregnancy. FDA said the recommendations are consistent with those of the task force created by the 21st Century Cures Act to identify and report on drug safety research and knowledge gaps for pregnant and nursing women. The agency will accept comments on the draft guidance through July 8.

Related News Articles

Headline
The U.S. Food and Drug Administration May 23 authorized marketing of a diagnostic test for detecting Zika virus antibodies in human blood.
Headline
Leaders of the Senate Committee on Health, Education, Labor and Pensions today released the Lower Health Care Costs Act of 2019 – bipartisan discussion draft…
Headline
The Joint Commission yesterday recommended that health care organizations review cleaning and disinfection instructions for tonometers and other ophthalmology…
Headline
A federal court in Texas yesterday ordered Pharm D Solutions to stop producing or distributing compounded drugs intended to be sterile until the company…
Blog
America’s hospitals and health systems are dedicated to doing everything possible for patients, particularly when they need emergency care and as a place for…
Headline
Hospitals, health systems and other health care organizations can sign up this week to host an intern for this year's Institute for Diversity and Health Equity…